Patients with prediabetes and nonalcoholic steatohepatitis (NASH) benefit nearly as much from pioglitazone therapy as those with type-2 diabetes, researchers report in the April issue of Clinical Gastroenterology and Hepatology. The diabetes drug reduced fibrosis in non-diabetic patients with NASH, the clinical study found, although to a lesser extent than in patients

Lamin A/C acts maintains hepatocyte nuclear shape and protects male mice from steatohepatitis by regulating growth hormone signaling and reducing activity of STAT1, researchers report in the November issue of Cellular and Molecular Gastroenterology and Hepatology. These observations show how variants in genes encoding lamins affect risk for steatohepatitis and liver fibrosis. Lamins are nuclear intermediate filament proteins that help form

Reducing dietary fructose for as little as 9 days decreases liver fat, visceral fat, and de novo lipogenesis and increases insulin sensitivity, secretion, and clearance in children with obesity and metabolic syndrome, researchers report in the September issue of Gastroenterology. These findings support efforts to reduce sugar consumption. Consumption of sugar

The human transmembrane 6 superfamily member 2 (TM6SF2) protein regulates cholesterol metabolism in mice, researchers report in the May issue of Gastroenterology. These findings provide insight into the how a variant of TM6SF2 (encoding the amino acid change E167K) reduces total cholesterol and low-density lipoprotein cholesterol (LDL-c) levels in humans, and

A special issue of Clinical Gastroenterology and Hepatology is dedicated to the clinical management of hepatic disorders, including nonalcoholic fatty liver disease (NAFLD), viral hepatitis, autoimmune hepatitis, and primary sclerosing cholangitis (PSC). The issue comprises 14 review articles that aim to present clinicians with evidence-based guidance and expert opinions on management of patients with liver

Two separate studies in the August issue of Gastroenterology show that weight loss, via diet or bariatric surgery, reduce features of non-alcoholic steatohepatitis (NASH). Eduardo Vilar-Gomez et al associated extent of weight loss, produced by lifestyle changes, with level of improvement in histologic features of NASH. The highest rates of NASH reduction

Modification of risk factors for cardiovascular disease—particularly dyslipidemia—is required to reduce morbidity and mortality in patients with nonalcoholic fatty liver disease (NAFLD). In a Perspective article published in the July issue of Clinical Gastroenterology and Hepatology, Kathleen E. Corey and Naga Chalasani discuss the increased risk of cardiovascular disease among patients with NAFLD, and strategies

About the Author

Dr. Kristine Novak is the science editor for Gastroenterology and Clinical Gastroenterology and Hepatology. She has worked as an editor at biomedical research journals and as a science writer for 15 years, covering advances in gastroenterology, hepatology, cancer, immunology, biotechnology, molecular genetics, and clinical trials. She has a PhD in cell biology and an interest in all areas of medical research.